WO2000067734A3 - Verwendung von phthalazine-derivaten - Google Patents

Verwendung von phthalazine-derivaten Download PDF

Info

Publication number
WO2000067734A3
WO2000067734A3 PCT/EP2000/003967 EP0003967W WO0067734A3 WO 2000067734 A3 WO2000067734 A3 WO 2000067734A3 EP 0003967 W EP0003967 W EP 0003967W WO 0067734 A3 WO0067734 A3 WO 0067734A3
Authority
WO
WIPO (PCT)
Prior art keywords
phthalazine derivatives
parp
inhibitors
disease
diseases
Prior art date
Application number
PCT/EP2000/003967
Other languages
English (en)
French (fr)
Other versions
WO2000067734A2 (de
Inventor
Wilfried Lubisch
Jens Sadowski
Michael Kock
Thomas Hoeger
Original Assignee
Basf Ag
Wilfried Lubisch
Jens Sadowski
Michael Kock
Thomas Hoeger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0202477A priority Critical patent/HUP0202477A3/hu
Priority to JP2000616761A priority patent/JP2003502286A/ja
Application filed by Basf Ag, Wilfried Lubisch, Jens Sadowski, Michael Kock, Thomas Hoeger filed Critical Basf Ag
Priority to SK1595-2001A priority patent/SK286676B6/sk
Priority to US09/959,404 priority patent/US6903098B1/en
Priority to AU50640/00A priority patent/AU5064000A/en
Priority to BR0010428-0A priority patent/BR0010428A/pt
Priority to KR1020017014342A priority patent/KR20020000642A/ko
Priority to DE50014190T priority patent/DE50014190D1/de
Priority to PL00352150A priority patent/PL352150A1/xx
Priority to CA002372704A priority patent/CA2372704A1/en
Priority to EP00934980A priority patent/EP1231982B1/de
Priority to IL14614800A priority patent/IL146148A0/xx
Publication of WO2000067734A2 publication Critical patent/WO2000067734A2/de
Priority to BG106056A priority patent/BG106056A/xx
Priority to NO20015462A priority patent/NO20015462L/no
Publication of WO2000067734A3 publication Critical patent/WO2000067734A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Phthalazin-Derivaten als Inhibitoren des Enzyms Poly(ADP-ribose)polymerase oder PARP (EC 2.4.2.30), die Verwendung als Inhibitoren von PARP-homologen Enzymen und insbesondere zeigen diese Phthalazin-Derivate auch eine selektive Hemmung der PARP-homologen Enzyme. In der Verwendung zur Herstellung von Arzneimitteln zur Behandlung von neurodegenerativen Krankheiten wie Alzheimersche Krankheit, Parkinsonsche Krankheit, Schlaganfall, Hirntrauma, Epilepsie, nierenschäden, kardiovaskularen Erkrankungen, Tumoren, rheumatische Erkrankungen, Diabetes mellitus etc.
PCT/EP2000/003967 1999-05-11 2000-05-03 Verwendung von phthalazine-derivaten WO2000067734A2 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PL00352150A PL352150A1 (en) 1999-05-11 2000-05-03 Use of phthalazine derivatives
DE50014190T DE50014190D1 (de) 1999-05-11 2000-05-03 Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
SK1595-2001A SK286676B6 (sk) 1999-05-11 2000-05-03 Použitie ftalazínových derivátov
JP2000616761A JP2003502286A (ja) 1999-05-11 2000-05-03 フタラジン誘導体の使用
AU50640/00A AU5064000A (en) 1999-05-11 2000-05-03 Use of phthalazine derivatives
BR0010428-0A BR0010428A (pt) 1999-05-11 2000-05-03 Uso de compostos
CA002372704A CA2372704A1 (en) 1999-05-11 2000-05-03 Use of phthalazine derivatives
HU0202477A HUP0202477A3 (en) 1999-05-11 2000-05-03 Use of phthalazine derivatives
US09/959,404 US6903098B1 (en) 1999-05-11 2000-05-03 Use of phthalazine derivatives
KR1020017014342A KR20020000642A (ko) 1999-05-11 2000-05-03 프탈라진 유도체의 용도
EP00934980A EP1231982B1 (de) 1999-05-11 2000-05-03 Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
IL14614800A IL146148A0 (en) 1999-05-11 2000-05-03 Use of phthalazine derivatives
BG106056A BG106056A (en) 1999-05-11 2001-10-26 Use of phthalazine derivatives
NO20015462A NO20015462L (no) 1999-05-11 2001-11-08 Anvendelse av fthalazinderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19921567A DE19921567A1 (de) 1999-05-11 1999-05-11 Verwendung von Phthalazine-Derivaten
DE19921567.7 1999-05-11

Publications (2)

Publication Number Publication Date
WO2000067734A2 WO2000067734A2 (de) 2000-11-16
WO2000067734A3 true WO2000067734A3 (de) 2002-06-20

Family

ID=7907632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003967 WO2000067734A2 (de) 1999-05-11 2000-05-03 Verwendung von phthalazine-derivaten

Country Status (20)

Country Link
US (1) US6903098B1 (de)
EP (1) EP1231982B1 (de)
JP (1) JP2003502286A (de)
KR (1) KR20020000642A (de)
CN (1) CN1399573A (de)
AT (1) ATE357272T1 (de)
AU (1) AU5064000A (de)
BG (1) BG106056A (de)
BR (1) BR0010428A (de)
CA (1) CA2372704A1 (de)
CZ (1) CZ20014038A3 (de)
DE (2) DE19921567A1 (de)
ES (1) ES2284499T3 (de)
HU (1) HUP0202477A3 (de)
IL (1) IL146148A0 (de)
NO (1) NO20015462L (de)
PL (1) PL352150A1 (de)
SK (1) SK286676B6 (de)
TR (1) TR200103236T2 (de)
WO (1) WO2000067734A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024796A1 (en) * 1999-10-01 2001-04-12 Smithkline Beecham Corporation 1,2,4-triazole derivatives, composition, process of making and methods of use
WO2001070674A1 (en) * 2000-03-20 2001-09-27 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2005501848A (ja) * 2001-08-15 2005-01-20 アイコス コーポレイション ２ｈ−フタラジン−１−オンおよびその使用方法
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
EP1527183B1 (de) 2002-07-26 2008-08-20 BASF Plant Science GmbH Neue selektionsverfahren
ATE552252T1 (de) 2002-10-01 2012-04-15 Mitsubishi Tanabe Pharma Corp Isochinolinverbindungen und deren medizinische verwendung
WO2004048339A1 (ja) 2002-11-22 2004-06-10 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
ATE541043T1 (de) 2005-03-08 2012-01-15 Basf Plant Science Gmbh Expressionsverstärkende intron-sequenz
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
US7994222B2 (en) * 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
BRPI0722070A2 (pt) * 2006-12-28 2014-04-08 Abbott Lab Inibidores de poli(adp-ribose)polimerase
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
KR20100102637A (ko) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2250282A4 (de) * 2008-02-04 2011-05-18 Bipar Sciences Inc Verfahren zur diagnose und behandlung von parp-vermittelten krankheiten
NZ591166A (en) 2008-08-06 2012-11-30 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EP2346495B2 (de) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmazeutische formulierung 514
CA2781835A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
CA2782014C (en) 2009-11-27 2021-08-31 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
BR112012012747A2 (pt) 2009-11-27 2015-09-29 Basf Plant Science Co Gmbh "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor célula hospedeira ou organismo não humano, método para fornecer a endonuclease quimérica, método para a recombinação homóloga dos polinucleotídeos e método para mutação direcionada de polinucleotídeos"
AU2011212928B2 (en) 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
BR112013009117A2 (pt) 2010-10-21 2016-07-19 Biomarin Pharm Inc sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
US9649394B2 (en) 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN103325380B (zh) 2012-03-23 2017-09-12 杜比实验室特许公司 用于信号增强的增益后处理
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
KR20190107656A (ko) 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
CN117897380A (zh) * 2021-08-17 2024-04-16 益方生物科技(上海)股份有限公司 哒嗪酮或吡啶酮化合物、其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2112389A (en) * 1981-12-29 1983-07-20 Nippon Kayaku Kk Esters of 4-hydroxymethyl-1- phthalazones
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0722936A1 (de) * 1994-08-09 1996-07-24 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
WO1998045292A1 (en) * 1997-12-02 1998-10-15 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
WO1999011649A2 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO2000005219A1 (en) * 1998-07-21 2000-02-03 Zambon Group S.P.A. Phthalazine derivatives as phosphodiesterase 4 inhibitors
WO2000005218A1 (en) * 1998-07-21 2000-02-03 Zambon Group S.P.A. Phthalazine derivatives phosphodiesterase 4 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5070700A1 (es) 1998-06-05 2001-08-28 Basf Ag Genes novedosos de (adp-ribosa) polimerasa

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2112389A (en) * 1981-12-29 1983-07-20 Nippon Kayaku Kk Esters of 4-hydroxymethyl-1- phthalazones
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0722936A1 (de) * 1994-08-09 1996-07-24 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
WO1999011649A2 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1998045292A1 (en) * 1997-12-02 1998-10-15 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
WO2000005219A1 (en) * 1998-07-21 2000-02-03 Zambon Group S.P.A. Phthalazine derivatives as phosphodiesterase 4 inhibitors
WO2000005218A1 (en) * 1998-07-21 2000-02-03 Zambon Group S.P.A. Phthalazine derivatives phosphodiesterase 4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNARD, A. M. ET AL: "A new and efficient synthesis of phthalazin-1(2H)-ones", SYNTHESIS (1998), (3), 317-320, XP001010445 *
MIYAZAKI, H. ET AL: "The use of stable isotopes in drug metabolism and pharmacokinetics", ADV. PHARMACOL. THER., PROC. INT. CONGR., 8TH (1982), MEETING DATE 1981, VOLUME 6, 227-33. EDITOR(S): YOSHIDA, HIROSHI: HAGIHARA, YASHIREO;EBASHI, SETSURO. PUBLISHER: PERGAMON, OXFORD, UK., XP001014487 *

Also Published As

Publication number Publication date
BG106056A (en) 2002-06-28
HUP0202477A2 (hu) 2002-12-28
NO20015462D0 (no) 2001-11-08
KR20020000642A (ko) 2002-01-05
WO2000067734A2 (de) 2000-11-16
CZ20014038A3 (cs) 2002-06-12
ES2284499T3 (es) 2007-11-16
EP1231982B1 (de) 2007-03-21
SK286676B6 (sk) 2009-03-05
IL146148A0 (en) 2002-07-25
JP2003502286A (ja) 2003-01-21
CN1399573A (zh) 2003-02-26
BR0010428A (pt) 2002-04-30
AU5064000A (en) 2000-11-21
ATE357272T1 (de) 2007-04-15
DE19921567A1 (de) 2000-11-16
HUP0202477A3 (en) 2003-02-28
DE50014190D1 (de) 2007-05-03
NO20015462L (no) 2001-11-08
TR200103236T2 (tr) 2004-08-23
PL352150A1 (en) 2003-07-28
EP1231982A2 (de) 2002-08-21
US6903098B1 (en) 2005-06-07
SK15952001A3 (sk) 2002-08-06
CA2372704A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000067734A3 (de) Verwendung von phthalazine-derivaten
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2001066564A3 (en) Gamma-secretase inhibitors
EP1353684B8 (de) Verwendung von dipeptidylpeptidase iv und aminopeptidase-n inhibitoren zur behandlung von ischämie-induzierter neurodegeneration
WO2001056567A8 (en) 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2003039454A8 (en) Beta-secretase inhibitors and methods of use
CA2257010A1 (en) Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
AU2002359161A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO1995009619A3 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2003028631A3 (en) Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
WO2001000566A3 (en) Substituted phenoxyacetic acids
WO2004082706A3 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
WO2003006443A3 (de) 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2006050359A3 (en) Pyridazine compounds and methods
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2005014576A8 (ja) イソキノリノン誘導体、その製造法および用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808074.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200108704

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 515029

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 106056

Country of ref document: BG

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2372704

Country of ref document: CA

Ref document number: 2372704

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15952001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1541/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011330

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001/03236

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 616761

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-4038

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020017014342

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 50640/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000934980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20010916A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020017014342

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-4038

Country of ref document: CZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09959404

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000934980

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017014342

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000934980

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-4038

Country of ref document: CZ